418 related articles for article (PubMed ID: 26438120)
21. Folliculotropism Does Not Affect Overall Survival in Mycosis Fungoides: Results from a Single-Center Cohort and Meta-Analysis.
Giberson M; Mourad A; Gniadecki R
Dermatology; 2017; 233(4):320-325. PubMed ID: 29169156
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
23. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.
Quaglino P; Maule M; Prince HM; Porcu P; Horwitz S; Duvic M; Talpur R; Vermeer M; Bagot M; Guitart J; Papadavid E; Sanches JA; Hodak E; Sugaya M; Berti E; Ortiz-Romero P; Pimpinelli N; Servitje O; Pileri A; Zinzani PL; Estrach T; Knobler R; Stadler R; Fierro MT; Alberti Violetti S; Amitay-Laish I; Antoniou C; Astrua C; Chaganti S; Child F; Combalia A; Fabbro S; Fava P; Grandi V; Jonak C; Martinez-Escala E; Kheterpal M; Kim EJ; McCormack C; Miyagaki T; Miyashiro D; Morris S; Muniesa C; Nikolaou V; Ognibene G; Onida F; Osella-Abate S; Porkert S; Postigo-Llorente C; Ram-Wolff C; Ribero S; Rogers K; Sanlorenzo M; Stranzenbach R; Spaccarelli N; Stevens A; Zugna D; Rook AH; Geskin LJ; Willemze R; Whittaker S; Hoppe R; Scarisbrick J; Kim Y
Ann Oncol; 2017 Oct; 28(10):2517-2525. PubMed ID: 28961843
[TBL] [Abstract][Full Text] [Related]
24. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
[TBL] [Abstract][Full Text] [Related]
25. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
26. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
27. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.
Elsayad K; Kriz J; Moustakis C; Scobioala S; Reinartz G; Haverkamp U; Willich N; Weishaupt C; Stadler R; Sunderkötter C; Eich HT
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1077-86. PubMed ID: 26581145
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China: A 12-Year Review.
Chen Z; Lin Y; Qin Y; Qu H; Zhang Q; Li Y; Wen Y; Sun J; Tu P; Gao P; Wang Y
JAMA Dermatol; 2023 Oct; 159(10):1059-1067. PubMed ID: 37585188
[TBL] [Abstract][Full Text] [Related]
29. Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.
Novelli S; García-Muret P; Mozos A; Sierra J; Briones J
Leuk Lymphoma; 2016 May; 57(5):1060-6. PubMed ID: 27096891
[TBL] [Abstract][Full Text] [Related]
30. Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndrome.
Calvani J; de Masson A; de Margerie-Mellon C; de Kerviler É; Ram-Wolff C; Gruber A; Meignin V; Brice P; Sadoux A; Mourah S; Bagot M; Battistella M
Br J Dermatol; 2021 Aug; 185(2):419-427. PubMed ID: 33400272
[TBL] [Abstract][Full Text] [Related]
31. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
32. Prognostic indicators for mycosis fungoides in a Greek population.
Nikolaou V; Papadavid E; Patsatsi A; Siakantaris M; Economidi A; Marinos L; Koletsa T; Georgiou E; Pappa V; Stratigos A; Antoniou C
Br J Dermatol; 2017 May; 176(5):1321-1330. PubMed ID: 27552962
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
Benner MF; Jansen PM; Vermeer MH; Willemze R
Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
[TBL] [Abstract][Full Text] [Related]
34. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
[TBL] [Abstract][Full Text] [Related]
35. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
36. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi-ethnic Asian cohort: a 12-year review.
Lim HLJ; Tan EST; Tee SI; Ho ZY; Boey JJJ; Tan WP; Tang MBY; Shen L; Chan YH; Tan SH
J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1513-1521. PubMed ID: 30801779
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.
Toro JR; Stoll HL; Stomper PC; Oseroff AR
J Am Acad Dermatol; 1997 Jul; 37(1):58-67. PubMed ID: 9216524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
